TUXUMDON POLIKISTOZ SINDROMINI ERTA TASHXISLASHDA FENOTIPIK STRATIFIKATSIYA, METABOLIK MARKERLAR VA PROGNOSTIK AHAMIYATI
##article.subject##:
tuxumdon polikistoz sindromi; fenotiplar; gipera ndrogenizm; metabolik buzilishlar; insulinga rezistentlik##article.abstract##
Relevance. Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of reproductive age and is characterized by pronounced clinical and metabolic heterogeneity. Phenotypic stratification enables a more accurate prognosis and individualized therapeutic approaches. Purpose. To evaluate the clinical, hormonal, and metabolic features of different PCOS phenotypes and to identify informative markers for early diagnosis of the disorder.
Materials and methods. A total of 145 patients with PCOS were examined and classified into four phenotypes according to the Rotterdam criteria (2003), along with 22 women in the control group. Clinical, ultrasound, hormonal, and metabolic parameters were assessed. Statistical analysis included regression models, ROC analysis, and neural network algorithms.
Results. The most unfavorable profile was found in phenotype A patients (obesity, insulin resistance, dyslipidemia, pronounced hyperandrogenism). Phenotype D was characterized by minimal alterations and was closest to the control group. Key markers of early PCOS diagnosis were menstrual cycle length, testosterone level, body mass index, ovarian volume, and antral follicle count. Conclusion. Phenotypic stratification and the use of diagnostically significant markers improve the accuracy of early PCOS diagnosis and allow the development of personalized management strategies.
Библиографические ссылки
Dewailly D, Lujan ME, Carmina E, et al. Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update. 2017;23(5):575–592.
Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018;14(5):270–284.
Kahal H, Kyrou I, Uthman OA, Randeva HS. Machine learning in the prediction of polycystic ovary syndrome: current state and future directions. Reprod Biomed Online. 2020;41(3):405–415.
Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Phenotypes and prevalence of polycystic ovary syndrome. Fertil Steril. 2016;106(1):6–15.
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Hum Reprod. 2004;19(1):41–47.
Teede HJ, Joham AE, Boyle J, et al. FIGO recommendations on polycystic ovary syndrome: An international expert consensus. Int J Gynaecol Obstet. 2023;163(2):323–341.
Teede HJ, Misso ML, Costello MF, et al. International evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33(9):1602–1618.
